OMERS Capital Markets Revenue and Competitors
Estimated Revenue & Valuation
- OMERS Capital Markets's estimated annual revenue is currently $22.5M per year.
- OMERS Capital Markets's estimated revenue per employee is $227,000
Employee Data
- OMERS Capital Markets has 99 Employees.
- OMERS Capital Markets grew their employee count by -8% last year.
OMERS Capital Markets's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Director/Portfolio Manager | Reveal Email/Phone |
2 | Director, Data & Analytics Delivery | Reveal Email/Phone |
3 | Director, Cross Asset Strategies | Reveal Email/Phone |
4 | Derivatives Trader | Reveal Email/Phone |
5 | Executive Assistant | Reveal Email/Phone |
6 | Business Analyst | Reveal Email/Phone |
7 | Multi-Asset Derivative Trading | Reveal Email/Phone |
8 | Trading Analyst | Reveal Email/Phone |
9 | Analyst, Global Multi-Asset Strategies | Reveal Email/Phone |
10 | Investment Analyst | Reveal Email/Phone |
OMERS Capital Markets Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $347.4M | 1093 | -1% | N/A | N/A |
#2 | $937.2M | 2949 | 9% | N/A | N/A |
#3 | $1.9M | 14 | 27% | N/A | N/A |
#4 | $53.2M | 213 | 7% | N/A | N/A |
#5 | $145M | 511 | 2% | N/A | N/A |
#6 | $2M | 15 | -17% | N/A | N/A |
#7 | $19.1M | 84 | 40% | N/A | N/A |
#8 | $3.7M | 23 | 5% | N/A | N/A |
#9 | $0.9M | 18 | 0% | N/A | N/A |
#10 | $4.6M | 29 | 26% | N/A | N/A |
What Is OMERS Capital Markets?
OMERS Capital Markets invests in companies with strong balance sheets and resilient business models. We partner with leading businesses, operators, and best-in-class investors to pursue traditional and innovative investment opportunities across the globe.
keywords:N/A
N/A
Total Funding
99
Number of Employees
$22.5M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
OMERS Capital Markets News
In 2014, it brought to market Peramivir, an influenza treatment. ... deal with Royalty Pharma and OMERS Capital Markets [the Canadian public...
In 2014, it brought to market Peramivir, an influenza treatment. ... deal with Royalty Pharma and OMERS Capital Markets [the Canadian public...
Founded in 2011, Dyal Capital is today the market's largest GP stakes investor. Last spring, Dyal merged with Owl Rock Capital Partners,...
Founded in 2011, Dyal Capital is today the market's largest GP stakes investor. Last spring, Dyal merged with Owl Rock Capital Partners,...
Other Companies in Toronto
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $24.8M | 99 | -3% | N/A |
#2 | $17.8M | 99 | 1% | N/A |
#3 | $15M | 99 | 50% | N/A |
#4 | $14.9M | 99 | -15% | N/A |
#5 | $11.9M | 99 | 13% | N/A |